For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search > PAD Profile : Guanfacine - Attention Deficit Hyperactivity Disorder (ADHD) - Children 6-17yrs
PAD Profile : Guanfacine - Attention Deficit Hyperactivity Disorder (ADHD) - Children 6-17yrs
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Atomoxetine hydrochloride
- Dexamfetamine sulfate
- Lisdexamfetamine dimesylate
- Methylphenidate hydrochloride
Other Indications
No indications returned.
Additional Documents
Committee Recommendations
Shared Care arrangements for children and adolescents with ADHD are in place with Surrey and Borders Partnership NHS Foundation Trust.
Guildford & Waverley, North West Surrey and Surrey Downs have agreed a Locally Commissioned Service (LCS) for practices entering into the shared care agreement with Surrey & Borders Partnership. The LCS supports the provision of an annual physical medication review by the GP (with an annual review by the specialist so that the patient continues to receive a 6-monthly review in accordance with the product license)
See below for a copy of the Shared care with LCS agreement
There is also a non-LCS shared care agreement that remains unchanged and is available for all non-LCS participating practices (see shared care agreement below)
The PCN recommends guanfacine as a treatment option in line with NICE guidance below (NG87 - March 2018).
Offer atomoxetine or guanfacine to children aged 5 years and over if
- they cannot tolerate methylphenidate or lisdexamfetamine
or
- their symptoms have not responded to separate 6-week trials of lisdexamfetamine and methylphenidate, having considered alternative preparations and adequate doses.
Guanfacine will be considered AMBER on the traffic light system with initiation by specialists in secondary care only.